Want to see GB:AVCT full AI Analyst Report?
AVCT Stock Chart & Stats
64.50 p
0.40 p(0.62%)
At close: 4:00 PM EDT
64.50 p
0.40 p(0.62%)
Day’s Range― - ―
52-Week Range48.00 p - 92.00 p
Previous CloseN/A
Volume605.24K
Average Volume (3M)816.35K
Market Cap
£313.83M
Enterprise Value342.34M
Total Cash (Recent Filing)£16.86M
Total Debt (Recent Filing)£14.92M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Oct 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding471,330,500
10 Day Avg. Volume902,069
30 Day Avg. Volume816,352
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Oncology Platform And Expanding IPThe pre|CISION platform shows potentially meaningful delivery and selectivity advantages, while expanding IP and dual-payload work may strengthen differentiation and support future partnering or commercial opportunities.
Progressing Clinical PipelineOn-time AVA6103 initiation and defined AVA6000 dosing demonstrate execution against development milestones. Continued enrollment and planned readouts could provide evidence needed to validate the platform clinically.
Improved Cost Control Supports DevelopmentLower administrative spending and reduced operating outflows indicate some cost discipline while the company advances its pipeline. This can extend the usefulness of available capital and preserve resources for priority clinical programs.
Bears Say
Persistent Losses And Cash ConsumptionThe business has not yet demonstrated self-funded economics: losses remain deep, revenue is small and volatile, and cash burn is worsening. Continued development therefore depends on external capital or future partnering proceeds.
Weakening Balance Sheet And Financial FlexibilityA shrinking equity and asset base, combined with meaningful debt, reduces financial flexibility and increases sensitivity to funding conditions. Ongoing losses may further weaken the balance sheet before products generate substantial revenue.
Dependence On Partners For Pivotal DevelopmentPivotal development and future commercialization depend on securing a partner, creating control and timing risk. If partnering is delayed, clinical progression, capital needs and the path toward meaningful revenue could all be extended.
Avacta Group plc News
AVCT FAQ
What was Avacta Group PLC’s price range in the past 12 months?
Avacta Group PLC lowest share price was 48.00 p and its highest was 92.00 p in the past 12 months.
What is Avacta Group PLC’s market cap?
Avacta Group PLC’s market cap is £313.83M.
When is Avacta Group PLC’s upcoming earnings report date?
Avacta Group PLC’s upcoming earnings report date is Oct 05, 2026 which is in 31 days.
How were Avacta Group PLC’s earnings last quarter?
Avacta Group PLC released its earnings results on May 19, 2026. The company reported -0.051 p earnings per share for the quarter.
Is Avacta Group PLC overvalued?
According to Wall Street analysts Avacta Group PLC’s price is currently Overvalued.
Does Avacta Group PLC pay dividends?
Avacta Group PLC does not currently pay dividends.
What is Avacta Group PLC’s EPS estimate?
Avacta Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avacta Group PLC have?
Avacta Group PLC has 471,330,500 shares outstanding.
What happened to Avacta Group PLC’s price movement after its last earnings report?
Avacta Group PLC reported an EPS of -0.051 p in its last earnings report. Following the earnings report the stock price went down -2.959%.
Which hedge fund is a major shareholder of Avacta Group PLC?
Currently, no hedge funds are holding shares in GB:AVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avacta Group plc Stock Smart Score
Company Description
Avacta Group PLC
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.
Technical Analysis
Nuformix Plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―